RCT for evaluation of a personalized online decision aid for colorectal cancer screening participation

No registrations found.

Ethical review Not applicable **Status** Recruiting

Health condition type -

Study type Interventional

Summary

ID

NL-OMON20959

Source

Nationaal Trial Register

Health condition

Colorectal cancer

Sponsors and support

Primary sponsor: ZonMW

Source(s) of monetary or material Support: ZonMW

Intervention

Outcome measures

Primary outcome

Decisional conflict

Secondary outcome

clarity of values, deliberation, anxiety, risk perception, intention to participate, usability and acceptability

1 - RCT for evaluation of a personalized online decision aid for colorectal cancer s ... 14-05-2025

Study description

Background summary

Most decisions in health care require a balancing of harms and benefits. Although people may make these decisions intuitively, informed decision making requires an explicit balancing of harms and benefits. Individuals making an informed decision therefore need to be aware of the harms and benefits relevant to their own situation. In situations with multiple outcomes, balancing harms and benefits for each of those outcomes to come to an overall decision may be challenging. The decision to participate in a nationwide screening program may be one of those situations, where different persons may weigh the potential harms and benefits of screening in different ways, and have a different risk profile for the screening condition. Benefit harm analyses can be used to assess the pros and cons of a decision in a quantitative way. Benefit-harm analyses can thereby help in tailoring the information and supporting the decision making of possible screening participants.

This RCT is part of a research project in which we aimed to develop a personalized web-based decision aid which enables indivuals to make a well-informed decision about participation in colorectal cancer (CRC) screening. First, we assessed the benefit-harm balance for FIT-based CRC screening versus no screening as a function of certain

characteristics and preferences of the invitees. We then developed a web-based decision aid based on the benefit-harm analysis, which visualized the benefit-harm balance for the individual. In this RCT, we will investigate whether participants who use this personalized deicison aid with benefit-harm assessment, are more certain about their decision whether to participate in CRC screening, as compared to participants who use a decision aid without such as personalized benefit-harm assessment. In addition, we will user-test the usability and acceptability of the deicison aid with benefit-harm assessment in the intervention arm of the study.

Study objective

Participants who use the decision aid with benefit-harm assessment have a lower mean score on the decisional conflict scale than participants who use the existing decision aid.

Study design

.Primary and secondary outcomes are measured in an online questionnaire after participants have used the decision aid. Participants decide for themselves when they want to participate in the study between July 5 and August 16

Intervention

using an online decision aid with benefit-harm assessment

Contacts

Public

Amsterdam UMC Linda Pluymen

0646798279

Scientific

Amsterdam UMC Linda Pluymen

0646798279

Eligibility criteria

Inclusion criteria

men and women aged 45-55 years

Exclusion criteria

none

Study design

Design

Study type: Interventional

Intervention model: Parallel

Allocation: Randomized controlled trial

Masking: Open (masking not used)

Control: Active

Recruitment

NL

Recruitment status: Recruiting

Start date (anticipated): 05-07-2021

Enrollment: 324

Type: Anticipated

IPD sharing statement

Plan to share IPD: Undecided

Ethics review

Not applicable

Application type: Not applicable

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

NTR-new NL9666

Other ZonMW: 2021/26866/ZONMW

Study results